Cancer & Oncology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

This Phase 3 trial is testing a new combination treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer who have not received prior therapy. The study focuses on patients with specific biomarkers and may offer an important new option that could improve survival. If successful, this approach could provide alternatives to current therapies for this type of lung cancer.

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

This Phase 3 study is exploring a targeted treatment combination for adults with metastatic colorectal cancer carrying a specific KRAS mutation. The goal is to improve the time patients live without the cancer worsening compared to standard chemotherapy options. Results from this trial may lead to new personalized treatments for this group of patients.

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This Phase 3 trial is looking at how long to give olaparib, a targeted therapy, in patients with advanced ovarian cancer who have certain genetic changes. It also tests whether adding bevacizumab affects outcomes. This study could help doctors decide the best length of treatment to keep cancer from returning after initial chemotherapy.

Letrozole After Tamoxifen in Treating Women With Breast Cancer

This completed Phase 3 trial tested letrozole, a hormone therapy, in women who finished five or more years of tamoxifen treatment for breast cancer. The goal was to see if letrozole could reduce the chance of cancer returning. The large study enrolled women across Canada and the United Kingdom and may support extended hormone treatment options.

Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt

This Phase 4 study examined the real-world effects of adding CDK4/6 inhibitors to hormone therapy for patients with a specific type of advanced breast cancer. Conducted in Egypt, it aims to show how well this combination works and its safety outside of clinical trials. Findings will help understand benefits for patients in everyday medical practice.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.